The biotechnology sector has emerged as the standout performer in the US IPO market, delivering exceptional returns that significantly outpace artificial intelligence-related listings. According to Bloomberg data, US initial public offerings of biotech and pharmaceutical companies this year have produced a weighted average return of 55%, creating a stark contrast with the 4.4% weighted average loss for the broader US IPO market. This performance has been bolstered by a 13% gain in the Nasdaq Biotechnology Index this year, contributing to the sector's strong momentum. As Bloomberg reports, this represents a dramatic shift from expectations that 2026 would be the year of AI and aerospace and defense listings, topped by SpaceX's record-setting IPO. Instead, shares of the 10 companies behind 2026's biggest US deals have slumped a weighted average of 6.3% as concern grows over whether the AI rally is overextended.
The biotech IPO momentum has translated into significant market activity, with at least six biotechs, led by CRISPR-based genetic medicines developer Scribe Therapeutics Inc., filing for IPOs this month. As reported by Bloomberg, these companies could price later in July and the first half of August before activity shuts down completely for the summer. The sector's IPO count for 2026 has already exceeded last year's tally of just eight listings, though this represents a relatively measured improvement compared to the more than 200 biotechs that went public during the unsustainable Covid pandemic market in 2020 and 2021. Jack Bannister from Leerink Partners describes this as "the healthiest biotech IPO market we have had in a long time," while Seth Rubin from Stifel Financial notes that "right now, you have some of the largest fund families in the world that are reallocating and pushing more capital into healthcare."
A significant factor supporting biotech performance has been the announcement of three major $10 billion or bigger buyouts in the past month. According to Bloomberg reports, these transactions include Abbvie Inc.'s purchase of Apogee Therapeutics Inc., GSK Plc's deal for Nuvalent Inc., and Vertex Pharmaceuticals Inc.'s purchase of Crinetics Pharmaceuticals Inc., which have boosted valuations and left investors with spare cash for IPO investments. The sector's IPO proceeds have topped $5 billion this year, representing three times last year's total. As Seth Rubin from Stifel Financial explains, "the returns in the small and mid-cap market has proven to investors there is a lot of upside," driving continued investor interest in biotech IPOs.
Individual biotech IPOs have demonstrated exceptional performance, with Veradermics Inc. up over 500% since its February debut, making it the best performing US IPO from any sector this year. As reported by Bloomberg, blood disorders-focused Hemab Therapeutics Holdings Inc. has more than doubled since its May IPO. Market experts, including Jack Bannister from Leerink Partners, describe this as "the healthiest biotech IPO market we have had in a long time," with Seth Rubin from Stifel Financial noting that "right now, you have some of the largest fund families in the world that are reallocating and pushing more capital into healthcare." Drivers of biotech and pharma's outperformance include a 13% gain in the Nasdaq Biotechnology Index this year, a more stable regulatory backdrop, notable trial data breakthroughs and acquisitions by big pharma companies.
